Phaseline

Companies › Pharmacosmos

Pharmacosmos: clinical trials, targets and expected readouts

3 active drug programs in 26 registered trials: 11 Phase 2, 8 Phase 4, 6 Phase 3, 1 Phase 1; Oncology, Hematology, Cardiovascular; next expected readout Apr 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Trilaciclib
Cyclin-dependent kinase 4 inhibitor; Cyclin-dependent kinase 6 inhibitor
CDK4, CDK6Phase 4Extensive-stage Small-cell Lung Cancer; Limited Stage Small Cell Lung Cancer; Osteosarcoma; Head and Neck Cancer Squamous Cell Carcinoma …Oct 2027
Ferric Derisomaltose
Iron delivery via carbohydrate complex; replenishes iron stores in iron-deficiency anemia
SLC11A2Phase 3Iron Deficiency, Anaemia in Children; Chronic Heart Failure; Perioperative Anemia; Iron Deficiency Anemia …Apr 2027
SP-420
Iron chelator
–Phase 2Beta Thalassemia Major AnemiaOct 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT05304442Ferric DerisomaltosePhase 3Anemia, Iron DeficiencyHematologyMar 2025
NCT06714383TrilaciclibPhase 2OsteosarcomaOncologyJul 2025
NCT06752798TrilaciclibPhase 2Head and Neck Cancer Squamous Cell CarcinomaOncologySep 2025
NCT05714007Ferric DerisomaltosePhase 4Perioperative AnemiaHematologyDec 2025
NCT06929936TrilaciclibPhase 2Non-Small Cell Lung CancerOncologyMay 2026
NCT04913649Ferric DerisomaltosePhase 4Iron Deficiency AnemiaHematologyNov 2026
NCT05578326TrilaciclibPhase 2Lung CancerOncologyDec 2026
NCT05978648TrilaciclibPhase 2Breast NeoplasmsOncologyDec 2026
NCT06992739TrilaciclibPhase 2NSCLC (Advanced Non-small Cell Lung Cancer)OncologyMar 2027
NCT05462704Ferric DerisomaltosePhase 3Iron Deficiency AnemiaHematologyMar 2027
NCT05179226Ferric DerisomaltosePhase 3Iron Deficiency, Anaemia in ChildrenHematologyApr 2027
NCT06898814Ferric DerisomaltosePhase 4Hip FractureHematologyJun 2027
NCT07490236TrilaciclibPhase 1TrilaciclibOncologyAug 2027
NCT05971732Ferric DerisomaltosePhase 4Heart Failure With Reduced Ejection FractionCardiovascularAug 2027
NCT05991128Ferric DerisomaltosePhase 4Heart Failure With Preserved Ejection FractionCardiovascularAug 2027
NCT06427343Ferric DerisomaltosePhase 4Heart FailureCardiovascularAug 2027
NCT06027268TrilaciclibPhase 2Metastatic Triple-Negative Breast CancerOncologyAug 2027
NCT06699472TrilaciclibPhase 2Ewing SarcomaOncologySep 2027
NCT05693909SP-420Phase 2Beta Thalassemia Major AnemiaHematologyOct 2027
NCT07473128TrilaciclibPhase 3Limited Stage Small Cell Lung CancerOncologyOct 2027
NCT06569485TrilaciclibPhase 2DLBCLOncologyDec 2027
NCT06929806Ferric DerisomaltosePhase 3Chronic Heart FailureCardiovascularDec 2027
NCT05407987Ferric DerisomaltosePhase 3Gynecologic CancerOncologyDec 2027
NCT05874401TrilaciclibPhase 4Extensive-stage Small-cell Lung CancerOncologyFeb 2028
NCT05929729Ferric DerisomaltosePhase 4IDA - Iron Deficiency AnemiaHematologySep 2028
NCT06698965TrilaciclibPhase 2Lung Cancer, Small CellOncologyOct 2029

Targets

CDK4 (1) CDK6 (1) SLC11A2 (1)

Companies with the same targets

Pfizer Novartis Eli Lilly Jiangsu HengRui Medicine Shandong Suncadia Medicine Chia Tai Tianqing Pharmaceutical Group Tasly Pharmaceuticals Jiangsu Simcere Pharmaceutical AstraZeneca Shanghai Hengrui Pharmaceutical

Companies built like this

Servier Affaires Médicales Guangzhou Gloria Biosciences Syntrix Biosystems Geron Dizal Pharmaceuticals

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.